This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Shares Jump On Positive GALNS Study Results

Updated with new information, stock price/

SAN RAFAEL, Calif. ( TheStreet) -- BioMarin Pharmaceuticals (BMRN - Get Report) said Monday that patients with a rare genetic disorder known Morquio A Syndrome were able to walk further following treatment with the company's experimental drug GALNS, satisfying the main goal of a late-stage study.

Based on the positive results from the Morquio A study, BioMarin plans to seek regulatory approval for GALNS in the first quarter of 2013.

BioMarin shares opened for regular trading Monday up 25% to $46.80. GALNS is seen as the most important drug in the BioMarin's pipeline, with the potential to double the company's revenue.

"We view the result as clearly positive for BioMarin and see it as a best-case outcome," writes JP Morgan analyst Cory Kasimov in a note to clients. Kasimov expects BioMarin shares to move higher not only because of GALNS' sales potential but because generalist investors will likely start buying BioMarin given the orphan drug experience with the Genzyme unit of Sanofi (SNY - Get Report)and Alexion Pharmaceuticals (ALXN - Get Report).

In patients with Morquio syndrome, also known as MPS IV, a missing enzyme prevents the breakdown of keratan sulftate in cells, leading to progressive skeletal and spinal cord malformation. GALNS is a replacement enzyme that reduces the harmful levels of keratin sulfate.

Morquio syndrome is a rare disease, with an estimated prevalence of between 1,000 and 1,500 patients in the U.S., Europe and Japan and between 1,500 and 2,000 patients in the rest of the world, BioMarin estimates.

In the phase III study, patients treated with a weekly infusion of GALNS were able to walk an average of 22.5 meters further in six minutes compared to patients treated with a placebo. The benefit in walking distance, the study's primary endpoint, was statistically significant.

BioMarin also tested an every other week dose of GALNS but walking distance was not improved compared to placebo.

Treatment with GALNS every week also demonstrated improved trends in three-minute stair climb and a statistically significant 41% reduction in keratan sulfite levels in the urine. Lung function in patients was also improved.

GALNS was shown to be generally well tolerated with adverse events similar to what's observed in other enzyme replacement therapies, BioMarin said.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALXN $141.41 0.00%
BMRN $82.14 0.00%
SNY $40.38 0.00%
AAPL $94.19 0.00%
FB $118.06 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs